Patrick A Zweidler-McKay
Overview
Explore the profile of Patrick A Zweidler-McKay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
2327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Watts B, Smith C, Evans K, Gifford A, Mohamed S, Erickson S, et al.
Hemasphere
. 2025 Jan;
9(1):e70063.
PMID: 39830370
Antibody-drug conjugates (ADCs) combining monoclonal antibodies with cytotoxic payloads are a rapidly emerging class of immune-based therapeutics with the potential to improve the treatment of cancer, including children with relapse/refractory...
2.
Hayashi R, Hermiston M, Wood B, Teachey D, Devidas M, Chen Z, et al.
Blood
. 2024 Mar;
143(20):2053-2058.
PMID: 38457359
Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children's Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or...
3.
Daver N, Montesinos P, DeAngelo D, Wang E, Papadantonakis N, Todisco E, et al.
Lancet Oncol
. 2024 Feb;
25(3):388-399.
PMID: 38423051
Background: Pivekimab sunirine (IMGN632) is a first-in-class antibody-drug conjugate comprising a high-affinity CD123 antibody, cleavable linker, and novel indolinobenzodiazepine pseudodimer payload. CD123 is overexpressed in several haematological malignancies, including acute...
4.
Fuentes-Mattei E, Bayraktar R, Manshouri T, Silva A, Ivan C, Gulei D, et al.
JCI Insight
. 2024 Feb;
9(3).
PMID: 38329131
No abstract available.
5.
Wood B, Devidas M, Summers R, Chen Z, Asselin B, Rabin K, et al.
Blood
. 2023 Aug;
142(24):2069-2078.
PMID: 37556734
The early thymic precursor (ETP) immunophenotype was previously reported to confer poor outcome in T-cell acute lymphoblastic leukemia (T-ALL). Between 2009 and 2014, 1256 newly diagnosed children and young adults...
6.
Gossai N, Devidas M, Chen Z, Wood B, Zweidler-McKay P, Rabin K, et al.
Blood
. 2023 Jan;
141(15):1802-1811.
PMID: 36603187
To determine the prognostic significance of central nervous system (CNS) leukemic involvement in newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL), outcomes on consecutive, phase 3 Children's Oncology Group clinical trials...
7.
Brady S, Roberts K, Gu Z, Shi L, Pounds S, Pei D, et al.
Nat Genet
. 2022 Sep;
54(9):1376-1389.
PMID: 36050548
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Here, using whole-genome, exome and transcriptome sequencing of 2,754 childhood patients with ALL, we find that, despite a generally low...
8.
Kannan S, Irwin M, Herbrich S, Cheng T, Patterson L, Aitken M, et al.
Antioxidants (Basel)
. 2022 Apr;
11(4).
PMID: 35453402
Acute myeloid leukemia (AML) is a molecularly heterogenous hematological malignancy, with one of the most common mutations being internal tandem duplication (ITD) of the juxtamembrane domain of the fms-like tyrosine...
9.
Dunsmore K, Winter S, Devidas M, Wood B, Esiashvili N, Chen Z, et al.
J Clin Oncol
. 2020 Aug;
38(28):3282-3293.
PMID: 32813610
Purpose: Nelarabine is effective in inducing remission in patients with relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) but has not been fully evaluated in those with newly diagnosed disease....
10.
Salzer W, Burke M, Devidas M, Dai Y, Hardy K, Kairalla J, et al.
J Clin Oncol
. 2020 Jun;
38(23):2628-2638.
PMID: 32496902
Purpose: The high-risk stratum of Children's Oncology Group Study AALL1131 was designed to test the hypothesis that postinduction CNS prophylaxis with intrathecal triple therapy (ITT) including methotrexate, hydrocortisone, and cytarabine...